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1  | INTRODUC TION
Systemic inflammation has been linked to chronic neurodegenera-
tive conditions, such as Alzheimer’s disease (AD), in multiple con-
texts.1 In epidemiological studies, chronic systemic inflammation 
has been prospectively associated with smaller brain volumes and 
poorer episodic memory in later life.2 In persons living with AD, 
systemic inflammation—both chronically at baseline and through 
acute episodes—predicted increased rates of cognitive decline.3 For 
individuals without a diagnosis of dementia, episodes of critical ill-
nesses have been associated with cognitive decline in later life.4 In 
population samples, individuals reporting symptoms of delirium have 
shown reduced cognitive performance at long- term follow- up.5,6
A number of risk factors for AD, such as educational attainment, 
physical activity, smoking, hypertension, obesity, diabetes, and depres-
sion, have been identified in large population- based studies.7 Some of 
these associations may operate via systemic inflammation, though 
these observations may also be affected by residual confounding. 
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Abstract
Epidemiological studies have implicated systemic inflammation in the development 
of Alzheimer’s disease (AD). However, these observations have been subject to re-
sidual confounding and reverse causation. We applied Mendelian randomization ap-
proaches to address this. We did not identify any causal associations between serum 
interleukin (IL)- 18, IL- 1ra, IL- 6, or erythrocyte sedimentation rate (ESR) concentra-
tions and AD. Our findings are limited by the low number of available instruments, 
though some of those identified (e.g., IL- 6) were of sufficient power to indicate true 
negative results. Taken together, it appears there is no evidence for a causal associa-
tion between these serum inflammatory cytokines and AD.
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Therefore, it remains uncertain whether systemic inflammation di-
rectly contributes to Alzheimer’s pathology, or reflects the contribu-
tions of other modifiable risk factors to AD. Yet, understanding if there 
are causal mechanisms between systemic inflammation and dementia 
would be vital if this presented a novel therapeutic target.
Mendelian randomization (MR) overcomes a number of limita-
tions when assessing causation from observational data.8 Using ran-
dom variations in genes of known function to study the causal effect 
of a modifiable exposure on a disease outcome, the susceptibility to 
confounding is reduced. In addition, the occurrence of genetic allo-
cation at the time of conception eliminates the likelihood of reverse 
causation. Although two recent MR studies have demonstrated no 
causal association between C- reactive protein (CRP), a broad marker 
of systemic inflammation, and dementia diagnosis,9,10 the potential 
causative associations between serum inflammatory cytokines and 
dementia diagnosis remain unknown. In this study, we first aimed to 
identify serum inflammatory cytokines with genetic instruments in 
current literature, and second, explore whether a causal association 
exists between individual serum inflammatory markers and AD diag-
nosis using a two- sample MR technique,11 which harnesses summary 
data available in literature from non- overlapping datasets and is less 
susceptible to weak- instrument bias observed in one- sample MR.12
2  | METHODS
The International Genomics of Alzheimer’s Project (IGAP) is a 
large two- stage study based upon genome- wide association stud-
ies (GWAS) on individuals of European ancestry. In stage 1, IGAP 
used genotyped and imputed data on 7 055 881 single nucleotide 
polymorphisms	 (SNPs)	 to	 meta-	analyze	 four	 previously	 published	
GWAS datasets consisting of 17 008 AD cases and 37 154 controls 
(the European Alzheimer’s Disease Initiative [EADI], the Alzheimer 
Disease Genetics Consortium [ADGC], the Cohorts for Heart and 
Aging Research in Genomic Epidemiology Consortium [CHARGE], 
and the Genetic and Environmental Risk in AD Consortium [GERAD]). 
In	stage	2,	11	632	SNPs	were	genotyped	and	tested	for	association	in	
an independent set of 8572 AD cases and 11 312 controls. Finally, a 
meta- analysis was performed combining results from Stages 1 and 2.
2.1 | Selecting genetic instruments for 
inflammation biomarkers
SNPs	for	inflammation	biomarkers	were	identified	using	the	NHGRI-	
EBI catalog of published GWAS studies (https://www.ebi.ac.uk/
gwas/home). GWAS studies of individuals of European descent were 
further	 examined,	 though	we	 could	only	 consider	 SNPs	 for	which	
complete data on minor allele frequency, beta coefficients, stand-
ard errors (SE), and P values were available. The catalogue search 
identified	22	SNPs	 from	 three	eligible	 studies	 for	 IL-	18,13,14 seven 
SNPs	 from	 two	 studies	 for	 IL1-	receptor	 antagonist	 (IL-	1ra),13,15 16 
SNPs	from	two	studies	for	IL-	6,16,17	and	four	SNPs	from	one	study	
for erythrocyte sedimentation rate (ESR).18
For	 all	 SNPs,	 a	 P value association threshold of 5 × 10−8 was 
applied for Bonferroni correction and a minor allele frequency 
>0.3.	 Where	 linkage	 disequilibrium	 amongst	 clumped	 SNPs	 was	
>0.2,	 the	 SNP	 with	 greatest	 beta	 coefficient	 was	 chosen	 as	 the	
index.	When	SNPs	from	the	two	samples	were	matched,	one	SNP	
for	 IL-	18	 (rs17229943),	 one	 for	 IL-	6	 (rs28638007),	 and	 one	 for	
ESR	 (rs11829037)	 did	 not	 correspond.	A	 suitable	 proxy	 SNP	with	
linkage disequilibrium of >0.8 could not be identified and these 
SNPs	were	excluded	 from	further	analysis.	Nine	SNPs	were	palin-
dromic	 (rs657152,	 rs4537545,	 rs7529229,	 rs4129267,	 rs4553185,	
rs4845618,	 rs4845625,	 rs4845371,	 and	 rs12740969),	 resulting	 in	
potential strand ambiguity. Allele frequencies for these were com-
pared between the inflammatory markers and IGAP datasets to en-
sure that effect estimates were recorded with respect to the same 
effect allele. The proportion of total variance explained for each in-
dependent was calculated by the following formula:
where MAF = minor allele frequency. For the two- sample MR anal-
ysis,	the	number	of	index	SNPs	used	for	IL-	18,	IL-	1ra,	IL-	6,	and	ESR	
was 2, 3, 3, and 4, respectively.
2.2 | Instrumental variables analyses in 
summary data
Two- sample MR was used to estimate the causal associations of 
each exposure (IL- 18, IL- 1ra, IL- 6, and ESR)13,15–18 on the outcome 
(AD diagnosis). First, inverse variance- weighted (IVW) regression 
was used to provide a combined estimate of the causal estimates 
(SNP-	Alzheimer’s/SNP-	biomarker)	from	each	SNP,	equivalent	to	a	
two- stage least squares analysis using individual- level data. All P 
values were two tailed. Second, in order to account for potential 
horizontal pleiotropy, MR- Egger was performed if three or more 
index	SNPs	were	available	 for	 the	biomarker,	 introducing	an	ad-
ditional parameter for unbalanced pleiotropy. In MR- Egger, linear 
regression	 of	 the	 SNP-	Alzheimer’s	 effect	 is	 performed	 on	 SNP-	
biomarker effect, where the slope represents the coefficient of 
the causal effect while the intercept represents the net bias attrib-
utable to horizontal pleiotropy. MR- Egger analyses assumed that 
individual	SNP	effects	on	the	outcome	were	independent	of	their	
pleiotropic effects (InSIDE assumption). All MR analyses methods 
should yield similar results in the absence of horizontal pleiotropy. 
All MR- Egger analyses were performed using the mregger package 
in Stata version 14.
3  | RESULTS
3.1 | Studies and participants
Genome- wide association data for inflammation markers were included 
from six meta- analyses or prospective studies with participants of White 
Caucasian ancestry. GWAS data for IL- 18 included 12 736 participants 
Variance explained=
(
β×
√
2×MAF(1−MAF)
)2
,
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(3233	from	Cardiovascular	Health	Study,	1210	from	InCHIANTI	study,	
and	8293	from	Finrisk	and	Cardiovascular	Health	in	Young	Finns	study);	
12 381 participants for IL- 1ra (3233 from Cardiovascular Health Study, 
1210	from	InCHIANTI	study,	7938	from	Whitehall	II	Study);	14	501	par-
ticipants	for	 IL-	6	(4911	Whitehall	 II,	3445	British	Women’s	Heart	and	
Health	Study,	and	6145	from	the	SarDINIA	Study);	and	data	on	6145	
participants were available for ESR. The variance in biomarker levels ex-
plained	by	selected	genetic	instruments	was	3.15%,	1.95%,	3.23%,	and	
2.99%	for	IL-	18,	IL-	1ra,	IL-	6,	and	ESR,	respectively.
3.2 | MR analysis
The causal odds ratios (OR) for the association between AD and 
individual inflammation markers are shown in Table 1. Using IVW 
regression, IL- 18, IL- 1ra, and IL- 6 did not appear to be causally as-
sociated with AD. Although IVW suggested a significant associa-
tion for ESR and AD, this estimate was attenuated when horizontal 
pleiotropy was taken into account, similar to the MR- Egger analyses 
for IL- 1ra and IL- 6. The degree of horizontal pleiotropy could not be 
tested for IL- 18 due to the lack of instrumental variables.
4  | DISCUSSION
In our study, no causal associations were found between serum 
IL- 18, IL- 1ra, IL- 6, or ESR concentrations and AD. The number of 
valid, independent genetic instruments for serum inflammatory cy-
tokines available in current published literature is limited. Overall, 
our findings do not support a causal role for inflammation on risk of 
Alzheimer’s dementia (see Table 2).
A strength of our approach was to use Mendelian random-
ization to investigate causal associations between serum inflam-
matory cytokines and diagnosis of AD, minimizing confounding 
and reverse causation observed in traditional epidemiological 
studies. We utilized the largest available genetic database for AD, 
with over 17 000 cases from over 50 000 samples.19 This study 
is also sufficiently powered for causal associations between IL- 6 
and Alzheimer’s dementia, and likely powered for IL- 18 and AD 
as suggested by power calculations using concentrations of cy-
tokines reported in the literature (http://cnsgenomics.com/shiny/
mRnd).20 These suggest that for power of 0.8 and type 1 error 
rate of 0.05, minimum sample sizes required for IL- 6 were 727 to 
5137,21,22 and from 3657 to 26 678 for IL- 18.23 Power calculations 
were not possible for ESR or IL- 1ra due to a lack of comparative 
serum levels in the literature between individuals with and with-
out AD.24 The main weakness of this study was the small num-
ber of genetic instruments for serum cytokines available in the 
current literature, limiting proportion of variance explained and 
TABLE  1 SNPs	identified	for	IL-	18,	IL-	1-	ra,	IL-	6,	and	ESR	from	current	literature
Biomarker Chromosome Position SNP
IGAP effect 
allele
Biomarker 
effect allele
Minor allele 
frequency
Variance 
explained (%)
IL- 18 2 32489851 rs385076 C C 0.34 2.65
IL- 18 11 112085316 rs2250417 T T 0.48 0.50
IL- 1ra 2 113834820 rs13386602 A A 0.44 0.83
IL- 1ra 2 113832333 rs6743376 A A 0.43 0.83
IL- 1ra 2 113874467 rs4251961 T T 0.32 0.29
IL- 6 14 52083080 rs1008924 A A 0.507 0.62
IL- 6 1 154426264 rs4129267 T A 0.41 0.31
IL- 6 9 136142355 rs643434 G G 0.742 2.30
ESR 1 207803021 rs11803956 T T 0.752 0.88
ESR 16 78019687 rs11861089 C T 0.694 0.57
ESR 1 207739127 rs3886100 A A 0.772 0.89
ESR 11 5306509 rs4910742 G A 0.934 0.65
ESR,	erythrocyte	sedimentation	rate;	IGAP,	International	Genomics	of	Alzheimer’s	Project;	IL,	interleukin;	SNPs,	single	nucleotide	polymorphisms.
TABLE  2 Mendelian randomization results for IL- 18, IL- 1ra, IL- 6, 
and ESR in Alzheimer’s disease
Biomarker No. SNPs Beta 95% CI P value
IL- 18
IVW 2 0.96 0.18 5.10 0.82
IL- 1ra
IVW 3 1.02 0.64 1.49 0.85
MR- Egger 1.04 0.25 4.27 0.96
IL- 6
IVW 3 1.00 0.96 1.03 0.78
MR- Egger 1.02 0.76 1.26 0.87
ESR
IVW 4 1.37 1.01 1.85 0.05
MR- Egger 1.62 0.39 6.63 0.50
CI, confidence interval; ESR, erythrocyte sedimentation rate; IL, inter-
leukin; IVW, inverse variance- weighted; MR, Mendelian randomization; 
SNPs,	single	nucleotide	polymorphisms.
4  |     TSUI and daVIS
assessments of horizontal pleiotropy. Second, our findings pertain 
only to people of European ancestry.
Is there scope for future studies investigating systemic inflammation 
and AD? Certainly further genetic associations may become evident if 
yet larger cohorts can establish stronger instruments for serum inflam-
matory cytokines. One approach would be multivariate GWAS within a 
single	sample	used	to	additionally	describe	SNP	effects	on	several	serum	
cytokines.25 In addition, the precision of AD diagnosis can be improved 
with better phenotyping, even with simple imaging. On current evi-
dence, however, it appears that causative associations between serum 
inflammation and AD cannot be demonstrated using this approach.
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